Full clinical approval requires stabilizing physiological decline rather than temporarily reducing surrogate biomarkers.
Regulators and clinicians are demanding long-term proof of stabilized physical organ function, such as glomerular filtration rates, rather than accepting transient protein reductions to grant definitive market access.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Trutakna's path to full approval requires showing stabilized long-term eGFR outcomes rather than just temporary protein clearance.
Full therapeutic validation for IgAN requires proving that a treatment permanently halts the decline of physiological kidney function rather than just lowering transient protein markers.
Full regulatory approval for the IgA nephropathy drug requires demonstrating long-term preservation of actual kidney filtration capacity rather than just temporary protein reduction.
Vera's Trutakna secured accelerated approval based on a surrogate biomarker but must demonstrate stabilized kidney function (eGFR) in a confirmatory trial to secure full, definitive approval.
Full regulatory approval for the drug depends on demonstrating the long-term stabilization of glomerular filtration rates rather than temporary proteinuria reduction.
The antisense program was terminated because successful biomarker reduction failed to translate into real-world functional stabilization for patients.